The GOOD DESIGN Awards is the oldest and most prestigious global awards program for design excellence and design innovation.
CELLINK’s flagship bioprinter, the BIO X, has won a GOOD DESIGN Award from The Chicago Athenaeum Museum of Architecture and Design and Metropolitan Arts Press Ltd. The Museum annually selects the most innovative and cutting-edge industrial, product and graphic designs produced around the world. CELLINK developed BIO X in 2017. The BIO X, patented in both the U.S. and in Europe, won a GOOD DESIGN Award in the medical category.
For over seven decades since its inception, The Chicago Athenaeum has honored both products and industry leaders in design and manufacturing that have chartered new directions and pushed the envelope for competitive products in the world marketplace.
When selecting winners, the GOOD DESIGN program emphasizes quality design of the highest form, function and aesthetics a standard beyond ordinary consumer products and graphics. The winners represent the ideals of a design process that embodies product excellence and endurance as well as a strong public identity.
Submissions to the program are judged by a jury of distinguished design professionals and leading industry specialists and design press on the highest aesthetic in terms of innovative design, new technologies, form, materials, construction, concept, function, utility, energy efficiency and sensitivity to the environment.
Every year, designers and manufactures in about 50 nations are honored for their achievements in producing hallmarks of contemporary design. Previous winners include a Boeing 787 Dreamliner and NASA spacecraft. CELLINK’s BIO X has been previously recognized for its innovative design by many prestigious awards, including the 2018 Red Dot Award and Stora Designpriset 2019.
For more information, please contact:
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: email@example.com.